A Case-control Study on the Clinical Characteristics of 28-day and 90-day Death From Severe Anthrax

Recruiting

• Conditions: Anthrax

• Registration Number: NCT06365073
• Lead Sponsor: Qin Ning

Brief Summary

This study is a clinical, multi-center, retrospective, case-control study. Patients clinically diagnosed with severe anthrax who meet the inclusion and exclusion criteria will be included in this study for analysis. Respiratory, circulation, nerve and other vital signs of patients with severe anthrax during hospitalization were recorded, and clinical data such as blood routine, blood biochemistry, coagulation function, myocardial injury, therapeutic drug use, and survival time of patients were recorded, as well as the survival situation of patients 28 days and 90 days after discharge.

Detailed Description

Not available

Study Timeline

• Study Start: 2024-03-13
• Status Verified: 2024-04
• Study First Submitted: 2024-04-10
• Study First Submitted QC: 2024-04-10
• Last Update Submitted: 2024-04-10
• Study First Posted: 2024-04-15
• Last Update Posted: 2024-04-15
• Primary Completion: 2024-08-31
• Study Completion: 2024-12-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

1. The typical bacilli with capsules were found in smear examination and culture of various secretions, excretions, blood and cerebrospinal fluid.
2. Multiple organ dysfunction (MODS) in brain, heart, liver, kidney, coagulation or more than one organ failure.

Exclusion Criteria

There are other conditions that affect short-term survival.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
mortality rates of severe anthrax	28 days and 90 days	mortality rates of severe anthrax

Secondary Outcome Measures

Name	Time	Method
the improvement in 28-day and 90-day mortality with treatment for severe anthrax	28 days and 90 days	the improvement in 28-day and 90-day mortality with treatment for severe anthrax
Peripheral blood biomarkers associated with 28-day and 90-day mortality	28 days and 90 days	Peripheral blood biomarkers associated with 28-day and 90-day mortality
incidence of complications	in hospital	To evaluate the incidence of respiratory, circulatory, neurological, digestive, coagulation and other complications of severe anthrax

Trial Locations

Locations (1)

Department of Infectious Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; 🇨🇳 Wuhan, Hubei, China